Holen Sie sich die Stockscreener-App
22.43
1.17%
0.26
Handel nachbörslich:
22.45
0.02
+0.09%
Schlusskurs vom Vortag:
$22.17
Offen:
$22.23
24-Stunden-Volumen:
469.36K
Relative Volume:
0.69
Marktkapitalisierung:
$1.04B
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
15.47
EPS:
1.45
Netto-Cashflow:
$173.19M
1W Leistung:
-1.32%
1M Leistung:
-7.43%
6M Leistung:
-0.09%
1J Leistung:
+10.98%
1-Tages-Spanne:
$22.15
$22.95
1-Wochen-Bereich:
$21.44
$23.14
52-Wochen-Spanne:
$11.16
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Vergleichen Sie PCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.43 | 1.05B | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Pacira BioSciences Inc. Stock Analysis and ForecastMarket-crushing stock picks - jammulinksnews.com
Pacira, JNJ in pact to boost Zilretta availability (PCRX) - Seeking Alpha
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts - The Manila Times
Major Expansion: J&J to Co-Promote Pacira's ZILRETTA Across 7M Annual Knee Injections Market - Stock Titan
What drives Pacira BioSciences Inc. stock priceRapid profit acceleration - jammulinksnews.com
Bank of New York Mellon Corp Decreases Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
What analysts say about Pacira BioSciences Inc. stockFree Stock Market Return Analysis - Autocar Professional
Is Pacira BioSciences Inc. a good long term investmentGame-changing capital returns - Autocar Professional
Zacks Research Has Negative Estimate for PCRX Q4 Earnings - Defense World
Teacher Retirement System of Texas Lowers Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Further Weakness as Pacira BioSciences (NASDAQ:PCRX) Drops 5.9% This Week, Taking Three-year Losses to 60% - 富途牛牛
Shareholders in Pacira BioSciences (NASDAQ:PCRX) have lost 60%, as stock drops 5.9% this past week - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRA) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Pacira BioSciences Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser
Pacira BioSciences Investors: Know Your Rights Amid Lawsuit - AInvest
Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit - PR Newswire
Principal Financial Group Inc. Increases Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Target Price at $26.44 - Defense World
Pacira BioSciences announces workforce reduction and facility changes By Investing.com - Investing.com Nigeria
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
What makes Pacira BioSciences Inc. stock price move sharplyFree Real-Time Stock Data - Newser
Pacira announces layoffs due to efficiencies in Exparel production - MSN
Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement - MSN
Allspring Global Investments Holdings LLC Makes New $277,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Pacira BioSciences (PCRX) Plunges 3.33% Amid Restructuring - AInvest
Pacira Pharmaceuticals Implements Workforce Reduction for Efficiency - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Pacira BioSciences announces workforce reduction and facility changes - Investing.com Australia
Pacira stock slips amid layoffs in U.S. (PCRX:NASDAQ) - Seeking Alpha
Pacira BioSciences announces workforce reduction - MarketScreener
GAMMA Investing LLC Increases Stock Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira Pharmaceuticals Secures New $300M Credit Facility - The Globe and Mail
Murano (MRNO) targets $500M for Bitcoin Treasury via new SEPA | PCRX SEC FilingForm 8-K - Stock Titan
Where are the Opportunities in (PCRX) - news.stocktradersdaily.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Pacira Issues Major Stock Compensation Package: 15,800 Shares Granted to New Executives - Stock Titan
PCRX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Pacira BioSciences, Inc. - ACCESS Newswire
State of Alaska Department of Revenue Has $635,000 Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Upper Peninsula ABC 10News, Sports, Weather and More from Michigan's Upper Peninsula - FinancialContent
Financial Contrast: Pacira BioSciences (NASDAQ:PCRX) & Antibe Therapeutics (OTCMKTS:ATBPD) - Defense World
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):